HSBC Securities upgraded Smith & Nephew from Hold to Buy
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/14/2025 | $37.50 | Outperform → Mkt Perform | Bernstein |
| 4/25/2025 | Buy → Hold | HSBC Securities | |
| 3/12/2025 | Buy → Neutral | UBS | |
| 11/6/2024 | Buy → Hold | Berenberg | |
| 11/1/2024 | Buy → Hold | Deutsche Bank | |
| 7/24/2024 | Buy | Deutsche Bank | |
| 6/5/2024 | Neutral → Buy | UBS | |
| 11/28/2023 | Underweight → Equal Weight | Barclays |
Smith+Nephew ((LSE:SN, NYSE:SNN), the global medical technology company, today announces findings from a newly published, first-of-its-kind comparative study of single-use negative pressure wound therapy (sNPWT) devices in orthopedic and cardiovascular surgery. Analyzing real-world data from over 22,000 patients in the Premier PINC AI™ Healthcare Database, the analysis reveals that prophylactic use of PICO sNPWT (-80 mmHg) significantly reduces the risk of wound dehiscence, hospital length of stay (LoS), and overall healthcare costs compared to the PrevenaTM -125 mmHg sNPWT device. Smith + Nephew's PICO Single Use Negative Pressure Wound Therapy System An estimated 313 million surgical
Smith+Nephew to continue as UFC's Preferred Sports Medicine Technology Partner Smith+Nephew ((LSE:SN, NYSE:SNN), the global medical technology company, and UFC the world's premier mixed martial arts organization, have announced a multi-year extension of their landmark worldwide marketing partnership forged in 2024. Under the renewal, Smith+Nephew will continue as UFC's Preferred Sports Medicine Technology Partner, a designation it received as UFC's inaugural partner in that category, to activate its brand around some of UFC's biggest events. "The continued growth of this partnership is a positive development for combat sports," said Robby Miller, Vice President, U.S. Global Partnership
Smith+Nephew ((LSE:SN, NYSE:SNN), the global medical technology company, today announces that the American Medical Association (AMA) CPT Editorial Panel has established a Category I Current Procedural Terminology (CPT) code for procedures involving its CARTIHEAL AGILI-C Cartilage Repair Implant, effective January 1, 2027. The new CPT code recognizes the clinical significance and growing adoption of the CARTIHEAL Implant, a single-stage, off-the-shelf solution for treating cartilage and osteochondral defects in the knee, including in patients with mild to moderate osteoarthritis (OA). The implant received Breakthrough Device Designation from the U.S. Food and Drug Administration and is the
Bernstein downgraded Smith & Nephew from Outperform to Mkt Perform and set a new price target of $37.50
HSBC Securities downgraded Smith & Nephew from Buy to Hold
UBS downgraded Smith & Nephew from Buy to Neutral
3 - SMITH & NEPHEW PLC (0000845982) (Reporting)
6-K - SMITH & NEPHEW PLC (0000845982) (Filer)
6-K - SMITH & NEPHEW PLC (0000845982) (Filer)
6-K - SMITH & NEPHEW PLC (0000845982) (Filer)